GeneNews Limited
TSX : GEN

GeneNews Limited

August 24, 2010 11:27 ET

New Study Demonstrates Value of ColonSentry™ as Pre-Screening Alert to Enhance Effectiveness of Colorectal Cancer Screening

TORONTO, ONTARIO--(Marketwire - Aug. 24, 2010) - GeneNews Limited (TSX:GEN), a company focused on developing blood-based biomarker tests for the early detection of diseases and personalized health management, announced that a poster describing a 786-cohort study entitled "Blood RNA Biomarker Detects Both Left- and Right-sided Colorectal Neoplasms" has been accepted for presentation at the Next Generation Dx Summit, held at the Ritz-Carlton in Washington, DC from August 24-26.

The poster reports on the application of a seven gene biomarker panel to 377 colorectal cancer ("CRC") patients and 409 controls. This seven gene biomarker panel forms the basis of the company's lead product, ColonSentry™, the world's first blood test to assess an individual's current risk for colorectal cancer. The poster concludes that the biomarker panel was able to detect right-sided CRC lesions across all stages with a sensitivity that is at least equal to the detection observed for left-sided lesions.

"Colonoscopy is widely regarded as the gold standard for colorectal cancer detection. Recent studies, however, suggest that its effectiveness is mostly confined to detection of tumors on the left side of the colon, with poor detection of right-sided lesions. Routine use of a blood test that can detect both left-sided and right-sided lesions could increase the effectiveness of colorectal cancer screening by revealing the potential presence of neoplasms in advance of colonoscopy," said Dr. Robert Burakoff, one of the investigators for the reported study, Clinical Chief of Gastroenterology and Director of the Center for Digestive Diseases and of the Crohn's and Colitis Center at Brigham and Women's Hospital, Harvard Medical School.

"We have long believed that widespread adoption ColonSentry™ would encourage more patients to engage in colorectal cancer screening, leading to earlier detection, improved patient outcomes and reduced healthcare costs. The results from this study further demonstrate the value of using ColonSentry™ as a routine test in advance of colonoscopy to provide a pre-screening alert, ultimately leading to enhanced colorectal cancer screening effectiveness," said Gailina J. Liew, President & Chief Operating Officer of GeneNews.

About GeneNews

GeneNews is an emerging molecular diagnostics company focused on the application of functional genomics to enable early diagnosis and personalized health management based on disease-specific biomarkers. The Company has a patented core platform technology, the Sentinel Principle®, which has the power to detect and stage virtually any disease or medical condition from a simple blood sample. GeneNews is currently applying the Sentinel Principle® in major areas with unmet clinical needs such as cancer, arthritis, cardiovascular disease and neurological disorders. GeneNews launched its first commercial product, ColonSentry™, a blood-based test to pre-screen and assess an individual's risk for colorectal cancer, in Canada in 2008. The company has engaged marketing partners in the US (Enzo Clinical Labs) and China (GeneDiagnostics Inc.) who are planning to launch ColonSentry™ in specific regions over the coming months. For more information on GeneNews and ColonSentry™, visit www.genenews.com or www.ColonSentry.com.

Forward-Looking Statements

This press release contains forward-looking statements, which reflect the Company's current expectations regarding future events. The forward-looking statements involve risks and uncertainties. Actual events could differ materially from those projected herein. Investors should consult the Company's ongoing quarterly filings and annual reports for additional information on risks and uncertainties relating to these forward-looking statements. The reader is cautioned not to rely on these forward-looking statements. The Company disclaims any obligation to update these forward-looking statements.

Contact Information